C. diff. Spores and More

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

“C. diff. Spores and More” is an educational program providing you with up-to-date information pertaining to C. diff. and Healthcare-Associated infections. Raising awareness through education and advocacy saves lives worldwide. Topics are of C. difficile infection (CDI) prevention, treatments, and environmental safety products along with Healthcare-Associated Infection (HAI) awareness and more. Our guests are topic experts discussing Antibiotic Resistance, Research and Development, Clinical trials, Nutrition Counseling, Microbiome, Mental health, C. diff. survivors, and so much more. Please join us every Tuesday at 10 AM Pacific Time on the VoiceAmerica Health and Wellness Channel.

  • Snag
  • ecard
  • Bookmark and Share

Nancy C. Caralla

Nancy C. Caralla, a three time C. diff. survivor, healthcare professional, and now dedicated to “Raising C. diff. Awareness” worldwide. Through the experiences is why we are so passionate raising C. diff. awareness. The C Diff Foundation was brought to fruition in November 2012 with a mission to educate and advocate for C. diff. infection prevention, treatment, and environmental safety worldwide. We now join the many successful hosts and programs on VoiceAmerica to deliver life-saving information through our program; “C. diff. Spores and More.”

  • Snag
  • ecard
  • Bookmark and Share

Episode Directory

August 2016

  • 8/23/2016: UV Intervention Addressing C. difficile and Other Pathogens Listen Now

July 2016

June 2016

May 2016

April 2016

March 2016

February 2016

January 2016

June 2015

May 2015

April 2015

March 2015

Dr. Guy de Bruyn, MD

Dr. Guy de Bruyn is Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. Previously he was a program director for HIV prevention studies in South Africa. Dr. de Bruyn earned his medical degree from the University of the Witwatersrand, South Africa and his Master’s in Public Health from the University of Washington, USA, where he was a senior fellow in the Division of Allergy & Infectious Diseases. He is a member of the American College of Physicians and the Infectious Disease Society of America. View Guest page

Episode Listing:

Dr Christian Felter, MD

Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Felter has 11 years of experience in medical affairs roles in the US and Europe, covering therapeutic areas including Immunology, Rheumatology, and Infectious Diseases. Prior to Joining Sanofi Pasteur he was with Astellas Pharma, where he was Global Medical Affairs Director responsible for the Infectious Disease portfolio. He was responsible for the European medical strategy for the Fidaxomicin launch in 2011. Dr. Felter also served in roles with Merck Serono, Cubist Pharmaceuticals, and Wyeth in the UK and US. View Guest page

Episode Listing:

Deverick J. Anderson, MD, MPH, FIDSA, FSHEA


Dr. Dev Anderson is an Associate Professor in the Division of Infectious Diseases and Department of Medicine at Duke University Medical Center. He is currently Director of the Duke Center for Antimicrobial Stewardship and Infection Prevention, Co-Director of the Duke Infection Control Outreach Network, and Chair of the Antimicrobial Stewardship and Evaluation Team at Duke University Hospital.
Dr. Anderson completed an Internal Medicine Residency at Duke University Medical Center in 2004. He completed a fellowship in Infectious Diseases at Duke University Medical Center in 2006. He received a Master of Public Health in Epidemiology from the University of North Carolina School of Public Health in May of 2007. Dr. Anderson has authored over 135 peer-reviewed articles related to hospital-acquired infections, infection control, hospital epidemiology, antibiotic stewardship, and multidrug-resistant organisms. View Guest page

Episode Listing:

Lewis Barrett, BS, MBA



Lewis Barrett, B.S., M.B.A., Senior Vice President, Commercial Strategy, Synthetic Biologics, Inc. a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases. View Guest page

Episode Listing:

Dr Whitney R Buckel, PharmD, BCPS


Dr. Whitney Buckel is the Infectious Diseases/Antimicrobial Stewardship Clinical Pharmacist for Intermountain Medical Center, in Murray, Utah. She also serves as the co-chair of the Intermountain System-wide Antimicrobial Stewardship Committee, overseeing stewardship efforts across 22 hospitals. Whitney graduated from Purdue University College of Pharmacy in 2010, and completed a PGY-1 Pharmacy Practice and PGY-2 Infectious Diseases residency at The Johns Hopkins Hospital. Her research interest is in the design, implementation and outcomes of antimicrobial stewardship initiatives. View Guest page

Episode Listing:

Dr. Steven Cagas, PhD


Dr. Steven Cagas is a Scientific Affairs Manager within Medical and Scientific Affairs within the Molecular Diagnostics Division of Roche Diagnostics Corporation. He has 5 years of industry experience at Roche. He directly interfaces with clinicians and key opinion leaders to assist in the commercialization of products within the Roche Molecular Diagnostics portfolio. He has spoken at several internal and external conferences as an invited speaker on various topics related to his areas of expertise. Dr. Cagas received his Ph.D. in Microbiology and Molecular Genetics from the University of Medicine and Dentistry of New Jersey (currently Rutgers University). His Ph.D. work focused on the study of the proteins expressed in the pathogenic fungus Aspergillus fumigatus. He used a novel approach to identify the proteins expressed at various stages of development as well as in response to an antifungal agent with both studies leading to high impact publications. View Guest page

Episode Listing:

Heather Clark



Our father, Paul Clark, spent six months hospitalized last year as he battled a C. diff. infection twice until his passing in June 2014. Witnessing our father’s battle with a C. diff. infection opened our eyes to the epidemic of healthcare-acquired infections and the thousands of Americans who lose their lives each year from a C. diff.infection with other diagnosis and infections involved. With my sister Kimberly, we are now active in efforts to raise C. diff. awareness, and volunteer for the C Diff Foundation, in hopes of helping to save lives. We work in honor of our father and look forward to the day when C. diff. infections will no longer be a threat in medical facilities worldwide. View Guest page

Episode Listing:

Dr. Martha Clokie



I obtained a BSc in Biology from Dundee University in 1996 an MSc in Biodiversity from Edinburgh University in 1997, and a PhD from Leicester in Molecular Ecology in 2001. I then did 6 years of Post-Doctoral research at the University of Warwick and in Scripps, La Jolla, San Diego. In 2007 I was appointed as a lecturer at Leicester, in 2011 a Reader and this year I was promoted to Professor in Microbiology. My research focuses on phages that infect bacterial pathogens of medical relevance and I have published 41 papers in this area. My major focus has been on Clostridium difficile where I have isolated a large phage collection. In vitro and in vivo data has shown that the viruses have therapeutic potential. I have filed a patent on these phages and am working with AmpliPhi to develop a product. I have had regular contact with the BBC and other media to talk about my work, and other phage projects, and have consulted to Science museum, London and Eden Project, UK to advise on bacteriophage displays. View Guest page

Episode Listing:

David Cook, Ph.D


David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. ("Seres"). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley View Guest page

Episode Listing:

Lisa Hurka Covington



I survived a fourteen month battle with a C.diff, infection beginning in 2012, which once again changed my life. My weight went from 125 pounds, to only 99. After taking over a dozen prescriptions of antibiotics trying to kill the beast, nothing worked except a fecal transplant (FMT), saving my life. Prayers are powerful. "Every negative situation has something positive that one day will evolve." View Guest page

Episode Listing:

Professor Simon Cutting


Professor Simon M. Cutting is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus subtilis. After spending 7 years in the renowned laboratory of Professor Richard Losick at Harvard University Biological Laboratories (USA) he spent 3 years as an Assistant Professor at the University of Pennsylvania Medical School in Philadelphia. He returned to the UK in 1996 and since then has worked on developing bacterial spores as novel oral vaccines at the Royal Holloway, University of London.The Cutting lab has developed a number of prototype oral vaccines and is now entering a ‘first in man’ phase 1/IIa clinical trial of a prototype oral vaccine to Clostridium difficile (www.cdvax.org). Proffesor Cutting is from t/ Royal Holloway University of London, UK, and Chairperson of t/C Diff Foundation’s Research & Development Committee. View Guest page

Episode Listing:

Sherrie Dornberger


NADONA/LTC is a nurse specialty organization representing the nurse leaders within the long term care continuum association with a mission to support and promote quality of care for those individuals receiving long term care, and concern for those delivering long term care. NADONA/LTC has nominated Sherrie Dornberger as their designated representative. Sherrie is the current Executive Director of NADONA/LTC, and is a Registered Nurse with 40+ years of experience in Nursing Administration, Long Term Care, and Infection Prevention. View Guest page

Episode Listing:

Renetta Dudzinski



I am a C.diff. survivor living in rural northern Illinois. It was a severe case with many recurrences and I am still recovering from side effects of the infection. The isolation, severe physical pain, missing her beloved son's wedding, and not being able to visit my elderly father has caused me great emotional pain. One positive avenue I have found to combat the emotional pain is by becoming a C Diff Foundation volunteer to raise C. diff. infection awareness at every opportunity and in every community. View Guest page

Episode Listing:

Veronica Edmond



As I celebrate seven years since conquering Stage III breast cancer, I also celebrate the miracle of overcoming a C.diff. infection. During my ordeal, I contracted C.diff. and it was a most horrific experience. I remember being quarantined for almost 20 days in the hospital, taking an arsenal of antibiotics, but nothing seemed to work. At the eleventh hour, an infectious disease specialist was summoned to my rescue. He prescribed a life-saving antidote, which quickly reversed my grim prognosis. Within days, the infection had cleared and I was released to go home. This total experience was nothing short of a miracle! I share more in my new book, My Glorious Opposite: The Other Side of Breast Cancer @ www.gloriousopposite.com View Guest page

Episode Listing:

Dr. Christian Felter, MD


Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Felter has 11 years of experience in medical affairs roles in the US and Europe, covering therapeutic areas including Immunology, Rheumatology, and Infectious Diseases. Prior to Joining Sanofi Pasteur he was with Astellas Pharma, where he was Global Medical Affairs Director responsible for the Infectious Disease portfolio. He was responsible for the European medical strategy for the Fidaxomicin launch in 2011. Dr. Felter also served in roles with Merck Serono, Cubist Pharmaceuticals, and Wyeth in the UK and US. View Guest page

Episode Listing:

Dr. Paul Feuerstadt, MD

A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training.His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections.Dr. Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT View Guest page

Episode Listing:

Carl Flatley


On April 30, 2002, Carl Flatley’s life changed. It was the day his daughter Erin died from septic shock, something Dr. Flatley, a retired endodontist, had never heard of. (Faces of Sepsis: Erin Flatley) After Erin’s death, Dr. Flatley learned everything he could about sepsis and he was astounded at what he – and millions of other Americans – didn’t know about the condition. He was shocked to learn that sepsis killed well over 200,000 people in the U.S. every year and affected so many more survivors. In 2004, Dr. Flatley founded the American Sepsis Alliance, which in 2007, became Sepsis Alliance. He made it his mission that sepsis would become as well known as cancer, diabetes, and other illnesses, and that as few people as possible would get sepsis, let alone die from it. His unending devotion to Erin’s memory has had a significant impact on many people. View Guest page

Episode Listing:

Dr. Patricia J. Freda Pietrobon, PhD

Dr. Patricia J. Freda Pietrobon, PhD: Associate Vice President, Research & Development Sanofi Pasteur Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Patricia began her career in diagnostic assay development with a focus on validation and quality alignment to regulatory requirements and GXPs. Patricia has been with Sanofi Pasteur for over 25 years and has contributed to the development and licensure of new bacterial & viral vaccines for pediatric & adult populations worldwide. View Guest page

Episode Listing:

Dr Kevin W Garey, PharmD, MS, FASHP


Chair, Department of Pharmacy Practice and Translational Research Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas
Kevin Garey, Pharm.D., M.S., is Chair of the Department of Clinical Sciences and Administration and Professor of Pharmacy Practice at the University of Houston College of Pharmacy in Houston, Texas. He also serves as Division Head, Experiential Therapeutics and Clinical Pharmacology. Additionally, he holds an academic appointment as Adjunct Associate Professor at the University of Texas School of Public Health in Houston.
Dr. Garey is an active member of the Society of Infectious Diseases Pharmacists and the American Society of Health-Systems Pharmacists (ASHP). His research interests include antimicrobial stewardship activities to prevent and treat Clostridium difficile infection, surgical site infections, and systemic candidiasis. He has received numerous national awards recognizing excellence in research, teaching, and publications. In 2010, Dr. Garey received the ASHP Best Practices Award in Health-System Pharmacy for implementation and validation of an antimicrobial stewardship program. View Guest page

Episode Listing:

Dr. Hudson Garrett


Dr. Garrett is a recognized international expert in infection prevention and control. Dr Garrett currently serves as the Chairperson of the Education Committee for the C Diff Foundation, and Vice President, Clinical Affairs PDI, Inc. and is a graduate of the Johns Hopkins Fellows Program in Infection Control and Hospital Epidemiology. He was honored as a Who’s Who for Infection Control by Infection Control Today Magazine in 2013 in recognition of his contributions to the field. View Guest page

Episode Listing:

Matthew Henn


Matthew Henn is the Senior Vice President and Head of Drug Discovery & Bioinformatics of Seres Therapeutics, Inc. He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications. Dr. Henn's research has focused on the development, implementation, and application of genomic technologies in the area of microbial populations and their metabolic functions. Prior to joining Seres, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. View Guest page

Episode Listing:

Dr. Lauri Hicks, DO


Dr. Hicks is a medical epidemiologist in the Division of Healthcare Quality Promotion, National Center for National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC). She is also a Commander in the US Public Health Service. Dr. Hicks attended medical school at the Philadelphia College of Osteopathic Medicine and completed her internal medicine residency and chief medicine residency at the University of Connecticut..In 2008, she became the medical director for the “Get Smart: Know When Antibiotics Work” program, which aims to educate healthcare providers and the public about appropriate antibiotic use. In 2015, she became the director for CDC’s new Office of Antibiotic Stewardship in the Division of Healthcare Quality Promotion to improve integration of stewardship across the spectrum of healthcare. She is an Adjunct Assistant Professor of Medicine at the Warren Alpert Medical School of Brown University. View Guest page

Episode Listing:

Cheryl Jones


Cheryl Jones is a grief counselor and a cancer educator who hosts Good Grief radio on the VoiceAmerica network. During her education as a Marriage and Family Therapist, her first wife was diagnosed with Multiple Myeloma, which was at the time a uniformly terminal illness with a six month to one-year prognosis. In the eight + years that followed, Cheryl engaged daily in the work of preparing for her death. They worked closely with Stephen and Ondrea Levine (Who Dies and Grieving Into Life and Death), learning to live with uncertainty. After her wife’s death in 1995, Cheryl immersed herself in her own multifaceted grief, surprised by frequent moments of joy. Cheryl is a consultant and group leader at the Women’s Cancer Resource Center (Oakland, CA), where she developed, manages and teaches in their Cancer, Illness and End of Life Continuing Education program. She also presents workshops integrating the arts, most particularly music, into explorations of grief. View Guest page

Episode Listing:

Lee Jones


Lee Jones, CEO and co-founder of Rebiotix Inc., is an experienced medical technology executive and serial entrepreneur. With deep experience in the medical devices industry and in managing and advising academic scientists on commercialization efforts, Rebiotix marks her first foray into biotechnology. She is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy (MRT). The company’s first MRT is a biologic drug targeted at recurrent Clostridium difficile infection. Rebiotix Founder, President, CEO, Privately held biotechnology company founded in 2011 Developing a new category of drugs to harness the human microbiome to treat disease; involves transplantation of live human-derived microbes; first target is recurrent Clostridium difficile infection, Led pioneering work with the US Food and Drug Administration to develop a new classification for the product – RBX2660 – completed Phase 2 clinical testing. View Guest page

Episode Listing:

Lee Jones



Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Most recently she was Chief Administrative Officer of the Schulze Diabetes Institute at the University of Minnesota, Minneapolis, MN and is the former president and chief executive officer of Inlet Medical. Inlet Medical was sold to Cooper Surgical in 2006. Her previous experience included fourteen years at Medtronic, Inc. where she developed and commercialized several innovative products that opened up new markets for the company. Lee has served on several public and private boards and is currently on the board of Electromed, Inc. She is a member of the Sofia Angel Investment Fund and is an adviser to several small companies. Ms. Jones has a BS in Chemical Engineering from the University of Minnesota and an Executive Management degree from the Carlson School of Management at the University of Minnesota. View Guest page

Episode Listing:

Dr. Nicholas Kartsonis


Dr. Nicholas Kartsonis , Associate Vice President of Clinical Research for Infectious Diseases for Merck Research Laboratories (MRL) and Section Head within MRL for antibiotics, antibacterials and cytomegalovirus shares his time and discusses the past, present, and future contributions of Merck Research Laboratories. Dr. Kartsonis joined Merck Research Laboratories in February 2000 and has been actively involved in programs for new antibacterials, antifungals, anti-HIV, anti-CMV, and agents targeted against C. difficile infection. Most recently, he has led the efforts to ensure the integration of the Cubist Pharmaceuticals clinical research portfolio within Merck. View Guest page

Episode Listing:

Dr Niranjan "Tex" Kissoon, MD


Dr. Kissoon is the Past President of the World Federation of Pediatric Critical and Intensive Care Societies, Vice-President, Medical Affairs at BC Children’s Hospital and Professor, Pediatric and Surgery (Emergency Medicine) Department of Pediatrics at the University of British Columbia in Vancouver, BC as well as he holds the University of British Columbia BC Children’s Hospital, Endowed Chair in Acute and Critical Care for Global Child Health. Dr. Kissoon is the vice chair of the Global Sepsis Alliance, co-chair of World Sepsis Day and the International Pediatric Sepsis Initiative.He has been involved in both advocacy and promoting Canada-wide involvement in World Sepsis Day as part of a global initiative and also involved in promoting sepsis guidelines. Dr. Kissoon was awarded a Distinguished Career Award by the American Academy of Pediatrics in 2013 for his contribution in the society. View Guest page

Episode Listing:

Shelby Lassiter, BSN,RN,CPHQ,CIC



Shelby holds an Associate Degree in Nursing from Wake Technical College and a Bachelor's Degree in Nursing from East Carolina University. She is certified in Infection Control (CIC) and is a Certified Professional in Healthcare Quality (CPHQ) through the National Association of Healthcare Quality (NAHQ). She has over thirty-five years of experience in healthcare: medical/surgical nursing, critical care, healthcare quality and infection prevention. Shelby has held a variety of positions in Infection Prevention and is currently an Infection Preventionist at a University Hospital located in North Carolina. View Guest page

Episode Listing:

Dr. Nathan A Ledeboer, PhD, D(ABMM)


Dr. Nathan A Ledeboer is an Associate Professor of Pathology at the Medical College of Wisconsin and the Medical Director of Microbiology and Molecular Diagnostics for Wisconsin Diagnostic Laboratories and Froedtert Health. His research endeavors, particularly in the area developing diagnostic tools for infectious diseases, have led to more than 70 publications in peer-reviewed journals and more than 100 funded research projects. Dr. Ledeboer is also a senior editor for the Journal of Clinical Microbiology. View Guest page

Episode Listing:

Dr Rosie Lyles MD



Dr. Lyles is Currently the Clinical Affairs Head, Research and Department, Clorox Healthcare and serves as the primary liaison for Client’s Healthcare division as a department head to relevant professional, research and academic institutions, public health agencies, and forums. The role will provide strategic guidance and assist with the development and implementation of a plan for clinical/scientific support of marketing initiatives. This includes overall responsibility for public health message development, publication planning, key opinion leader development and provides relevant input into the clinical and product intervention design and development View Guest page

Episode Listing:

Cliff McDonald, MD



Cliff McDonald, MD, graduated from Northwestern University Medical School, completed his Internal Medicine Residency at Michigan State University and an Infectious Diseases Fellowship at the University of South Alabama, following which he completed a fellowship in Medical Microbiology at Duke University. Past positions have included Associate Investigator at the National Health Research Institutes in Taiwan and Assistant Professor in the Division of Infectious Diseases at the University of Louisville. Dr. McDonald is a former Epidemic Intelligence Service officer and former Chief of the Prevention and Response Branch in the Division of Healthcare Quality Promotion at the Center for Disease Control and Prevention (CDC), where he currently serves as the Senior Advisor for Science and Integrity. He is the author or co-author of over 100 peer-reviewed publications with his main interests in the epidemiology and prevention of healthcare-associated infections, especially Clostridium difficile (C.diff.) infections, and the prevention of antimicrobial resistance. View Guest page

Episode Listing:

Clifford McDonald, MD


Dr. McDonald graduated from Northwestern University Medical School, completed his Internal Medicine Residency at Michigan State University, and an Infectious Diseases Fellowship at the University of South Alabama, following which he completed a fellowship in Medical Microbiology at Duke University. Past positions have included Associate Investigator at the National Health Research Institutes in Taiwan and Assistant Professor in the Division of Infectious Diseases at the University of Louisville. Dr. McDonald is a former officer in the Epidemic Intelligence Service and former Chief of the Prevention and Response Branch in the Division of Healthcare Quality Promotion at the CDC where he currently serves as Senior Advisor for Science and Integrity in the same division. He is the author or co-author of over 100 peer-reviewed publications with his main interests in the epidemiology/prevention of HAI's, especially Clostridium difficile infections, and prevention of antimicrobial resistance. View Guest page

Episode Listing:

James McIlroy


James McIlroy is a senior medical student at the University of Aberdeen in Scotland. Previously, he earned his Bachelors in Medical Sciences with Honors in human Physiology at the University of Edinburgh. At the present time, James is undertaking a prestigious fellowship at the Royal Society of Edinburgh. During his time at medical school, James identified an unmet need for safe access to fecal microbiota transplantation (FMT) within the United Kingdom. He subsequently established a not-for-profit community interest company called EuroBiotix CIC, which seeks to support clinicians within the UK National Health Service provide FMT. View Guest page

Episode Listing:

Dr. Caterina Oneto, MD

Dr. Caterina Oneto is a Clinical Assistant Professor within the NYU Division of Gastroenterology, Board Certified in Gastroenterology and Internal Medicine.
Fluent in Spanish, she graduated with a degree in Medicine and Surgery from the Universidad de Valparaiso in Chile. She completed her residency in Internal Medicine at Cabrini Medical Center, where she served also as Chief Resident, and later completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine.
With expertise in endoscopy, colonoscopy, capsule endoscopy, liver and pancreatic diseases, Dr. Oneto’s special interests include IBD (Crohn’s disease and Ulcerative Colitis), IBS (irritable bowel syndrome), microbiota modification, treatment of Clostridium Difficile and FMT (Fecal Microbiota Transplantation). View Guest page

Episode Listing:

Dr Mark Pimentel MD, FRCP(C)


Mark Pimentel, MD, FRCPC, is Director of the GI Motility Program and Laboratory at Cedars-Sinai, Associate Professor of Medicine at CSMC and Professor of Medicine at UCLA Geffen School of Medicine in Los Angeles, CA. Dr. Pimentel completed three years of undergraduate degree with honors in microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree and his BSc(Med) from the Univeristy of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic sciences, transitional, and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease. View Guest page

Episode Listing:

Ray Schachter


“I miraculously survived acute Sepsis in 1996 due to extensive medical intervention and have experienced the immediate and long-term consequences on me and my family. I am the Chair of the GSA Task Force whose goal is to have the UN mandate Sepsis as a World Health Day. Working with these very accomplished and committed people from GSA, many of whom are on the GSA Executive or Ambassadors, on this important project is a very special opportunity.” View Guest page

Episode Listing:

Professor Nancy Sheridan



Nancy Sheridan is a full time, Associate Professor at the Fashion Institute of Technology and a winner of the prestigious SUNY Chancellor’s Award for Excellence in Teaching. Professor Sheridan has been teaching since fall 2000 in the Fashion Merchandising Management Department within the School of Business and Technology. For the past seven years, she has also taught a Retail Merchandising course at the University of Pennsylvania, Wharton Business School to undergraduate and MBA students. View Guest page

Episode Listing:

Dr Sushma Shivaswamy, PhD

Dr Sushma Shivaswamy, Vice President of Research and Development; Dr. Shivaswamy joined XBiotech in May 2009 as a Senior Research Scientist and quickly advanced to lead the R&D group as Director of Research. Dr. Shivaswamy's academic studies involved elucidating mechanisms for regulation of gene expression. Prior to joining XBiotech, Dr. Shivaswamy was a postdoctoral researcher a the Center for Systems and Synthetic Biology at the University of Texas of Austin. She has a Ph.D. degree in Molecular Biology from the Center of Cellular and Molecular Biology, India. View Guest page

Episode Listing:

Sarah Simmons, MPH CIC



Science Director, Xenex

As an epidemiologist, Sarah Simmons works with customers to implement Xenex's pulsed xenon UV light room disinfection technology in their facility, provide support for customers' Infection Prevention departments, and evaluate their infection reduction results for publication in scientific journals. Sarah worked as an Infection Preventionist for five years in San Antonio, with a focus on infection prevention in critical care. She is a member of the San Antonio APIC chapter and has served on the board in numerous roles. Sarah is a Doctoral Candidate at the University of Texas School of Public Health, has a Masters of Public Health in Epidemiology and Biostatistics from the Texas A&M School of Rural Public Health, and a Bachelors degree in Biology from Texas A&M University. View Guest page

Episode Listing:

Dr Joseph Sliman MD


MPH,Senior Vice President, Clinical & Regulatory Affairs. Dr. Sliman joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University View Guest page

Episode Listing:

Dr Joseph Sliman, MD, MPH



Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs, Synthetic Biologics, Inc. a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases. Presentation Topic: "Oral Enzyme Therapy to Protect the Gut Microbiome from the Harmful Effects of IV Antibiotics for the Prevention of Clostridium difficile Infection (CDI) View Guest page

Episode Listing:

Arjun Srinivasan, MD



Dr. Srinivasan, MD, is Associate Director for healthcare-associated infection prevention programs in the Division of Healthcare Quality Promotion at the Center for Disease Control and Prevention’s National Center for Emerging and Zoonotic Infectious Diseases. Dr. Srinivasan is also a captain in the US Public Health Service. An infectious disease doctor, Dr. Srinivasan oversees several CDC programs aimed at eliminating healthcare-associated infections and improving antibiotic use. For much of his CDC career, Dr. Srinivasan ran the healthcare outbreak investigation unit, helping hospitals and other healthcare facilities track down bacteria and stop them from infecting other patients. Today, Dr. Srinivasan leads CDC’s work to improve antibiotic prescribing and works with a team of CDC experts researching new strategies to eliminate healthcare-associated infections. View Guest page

Episode Listing:

Dr Michael Stecher MD

Dr Michael Stecher is the Medical Director of XBiotech. Dr. Stecher has served as Medical Director since June 2010 and has worked to develop XBiotech's Clinical Program to treat Chronic Inflammatory Disease through targeting the interleukin-1 system, collaborating with key opinion leaders in fields of Endocrinology, Oncology, Cardiovascular medicine, and Dermatology. Dr. Stecher is Board Certified in Family Medicine and a graduate from the University of Kansas School of Medicine. View Guest page

Episode Listing:

Dr. Mark Stibich, PhD


Dr Mark Stibich, a co-founder of Xenex, Mark oversees scientific research, new technology development, and protocol design. An epidemiologist who has published many scientific papers about Pulsed Xenon technology, Mark is also an inventor on multiple patents. Originally from Dayton, OH, Mark graduated from Yale and the Johns Hopkins University School of Public Health, where he earned a Masters in Health Science and PhD. Mark’s interest in public health has taken him to many distant countries. He served as a Peace Corps health volunteer and then trained Peace Corps health volunteers in Ulaanbaatar, Mongolia. He has conducted research in Russia, Tajikistan, Afghanistan, South Africa, Kenya, the U. S., and Brazil. In addition, he has received grants for and directed HIV/AIDS research and intervention projects throughout Russia and has been a consultant with the USAID project. View Guest page

Episode Listing:

Mark Stibich, PhD



Chief Scientific Officer & Co-founder, Xenex

Dr. Stibich is a founder of Xenex and, as its Chief Scientific Officer, he oversees scientific research, product development, facility assessments, and protocol design. He leads new technology development and is an inventor on multiple patents. Dr. Stibich meets frequently with infection prevention representatives at healthcare facilities, helping them understand and solve their infection control challenges while analyzing hospital results. Dr. Stibich holds a doctoral degree from the Johns Hopkins University School of Public Health, a Masters in Health Science, also from Johns Hopkins, and a bachelor’s degree from Yale University. He has conducted research in Russia, Tajikistan, Afghanistan, South Africa, Kenya, the United States and Brazil. View Guest page

Episode Listing:

Glenn Taylor


Glenn Taylor is the Microbiologist at the Taymount Clinic just outside London in the UK. Glenn has spent >+ 5 years researching the commensal colonization of bacteria in the human digestive system. Following a breakthrough in the understanding of mutation for environmental advantage in bacterial DNA, the Taymount Clinic has developed a method of addressing mutation to improve host engraftment. The clinic is now investigating how the process of increasing the diversity and density of beneficial gut bacteria has an effect on disease conditions other than the treatment of a Clostridium difficile (aka C.diff.) infection. View Guest page

Episode Listing:

Dr Casey Theriot



Dr. Theriot’s research focuses on defining the gastrointestinal tract microbiome and metabolome during different disease states to understand how perturbations to this system affect human health. Colonization resistance describes the ability of the gastrointestinal tract to prevent colonization by pathogens. Currently, she is exploring the interactions between the gut microbiota and the pathogen Clostridium difficile, a significant and re-emerging public health problem. C. difficile infection (CDI) is the leading nosocomial infection in the United States. A major goal of her work is to create an integrated model of the complex interactions among the gut microbiota, pathogen and host. To accomplish this she integrates data obtained from high-throughput methods that analyze the gut microbiome, metabolome and host immune responses in mouse models and human biological specimens. View Guest page

Episode Listing:

Jeanine Thomas


Ms. Thomas founded MRSA Survivors Network in early 2003 due to having been critically ill with a MRSA infection, sepsis and C. difficile. Her organization was the first in the U.S. to raise the alarm about the MRSA epidemic, healthcare-acquired infections (HAI’s) and antibiotic resistance (AMR) to state and federal health officials in the U.S. View Guest page

Episode Listing:

Kelly Thornburg

Mr. Thornburg joined XBiotech as Senior Vice President of Operations in June 2015. In this capacity Mr.Thornburg will be responsible for Manufacturing & Quality functions. Prior to joining XBiotech, Mr. Thornburg worked at Amgen, Inc. for sixteen years, most recently serving as the Executive Director Quality Site Head at the Amgen Colorado manufacturing site. He was responsible for all aspects of Quality Operations including QA, QC, Validation, Compliance, and GMP Training. In his tenure at Amgen, Mr. Thornburg supported approval and commercialization of four new protein therapeutic products, provided leadership at both the Colorado and Puerto Rico Operations sites, and worked extensively on regulatory filing activities and technology transfer projects. Prior to Amgen, Mr. Thornburg worked in analytical research and development roles for a variety of Pharmaceutical and contract laboratory organizations. He received a B.S. degree in Chemistry from Rockhurst College, Kansas City, MO View Guest page

Episode Listing:

Michele (Shelley) Trucksis, Ph.D, M.D


Michele (Shelley) Trucksis is the Executive Vice President and Chief Medical Officer of Seres Therapeutics, Inc. ("Seres"). Dr. Trucksis has 25 years of experience in medicine and infectious diseases. Prior to joining Seres, she served as Executive Director of Merck Research Laboratories with responsibility for clinical and global product development functions and development strategy in antibacterials, antifungals, and anti-cytomegalovirus drug candidates. Dr. Trucksis earned her B.S. in medical technology from Youngstown State University, her Ph.D. in biochemistry from Kent State University, and her M.D. from Case Western Reserve School of Medicine. She completed her internship and residency in Internal Medicine at Yale-New Haven Hospital and her infectious diseases fellowship training at the Massachusetts General Hospital of Harvard Medical School. View Guest page

Episode Listing:

Dr. Richard Vickers


Richard Vickers joined Summit Therapeutics company in 2003 and has served as their Chief Scientific Officer, Antimicrobials, since October 2013. During his time at the Summit Therapeutics company, Dr. Vickers has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs, including our antibiotic program for the treatment of CDI. Prior to joining Summit, Dr. Vickers undertook postdoctoral research studies with Professor Stephen Davies at the University of Oxford and held a Stipendiary Lectureship in organic chemistry at St. Catherine's College in Oxford.
...
Dr. Vickers received a Ph.D. in organic chemistry from the University of Reading and a B.Sc. in chemistry from King's College London. View Guest page

Episode Listing:

Bradley Whitchurch



Brad Whitchurch is the Founder, CEO and Chairman of the Board at Seal Shield LLC. Seal Shield is an infection control solutions manufacturer headquartered in Jacksonville, FL. The Company produces waterproof, antimicrobial input devices for healthcare and other global markets. Seal Shield’s primary products include washable, antimicrobial keyboards, mice and TV remote controls. Mr. Whitchurch has been a pioneer in the computer products industry for 25 years. Prior to founding Seal Shield in 2006, Mr. Whitchurch served as President at Embassy Sales, Senior VP of Sales and Marketing for Unotron Inc., Director of Sales with Actiontec Electronics, and in various roles with computer product distributors including Tech Data, Ameriquest, and Computer 2000. Mr. Whitchurch is the inventor of numerous waterproof devices and holds seven patents on waterproof technology. Brad Whitchurch is a Florida native, graduate of Rollins College, and resides in Florida with his wife and two sons. View Guest page

Episode Listing: